PHARVARIS N.V. EO -12 (9EN) - Net Assets
Based on the latest financial reports, PHARVARIS N.V. EO -12 (9EN) has net assets worth €271.27 Million EUR (≈ $317.15 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€301.45 Million ≈ $352.43 Million USD) and total liabilities (€30.18 Million ≈ $35.28 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. See PHARVARIS N.V. EO -12 net asset quality index to measure how much of total assets are equity-financed.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €271.27 Million |
| % of Total Assets | 89.99% |
| Annual Growth Rate | 7.26% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 77.21 |
PHARVARIS N.V. EO -12 - Net Assets Trend (2021–2025)
This chart illustrates how PHARVARIS N.V. EO -12's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 9EN market cap.
Annual Net Assets for PHARVARIS N.V. EO -12 (2021–2025)
The table below shows the annual net assets of PHARVARIS N.V. EO -12 from 2021 to 2025. Also explore PHARVARIS N.V. EO -12 (9EN) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €271.27 Million ≈ $317.15 Million |
+1.31% |
| 2024-12-31 | €267.76 Million ≈ $313.04 Million |
-30.28% |
| 2023-12-31 | €384.05 Million ≈ $448.99 Million |
+157.30% |
| 2022-12-31 | €149.26 Million ≈ $174.50 Million |
-27.17% |
| 2021-12-31 | €204.95 Million ≈ $239.61 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to PHARVARIS N.V. EO -12's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 49202790600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €850.87 Million | 313.66% |
| Total Equity | €271.27 Million | 100.00% |
PHARVARIS N.V. EO -12 Competitors by Market Cap
The table below lists competitors of PHARVARIS N.V. EO -12 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FLEX LNG Ltd
NYSE:FLNG
|
$1.67 Billion |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
$1.67 Billion |
|
Pebblebrook Hotel Trust
NYSE:PEB
|
$1.67 Billion |
|
Usha Martin Limited
NSE:USHAMART
|
$1.67 Billion |
|
Yifan Xinfu Pharmaceutical Co Ltd
SHE:002019
|
$1.67 Billion |
|
Molymet
SN:MOLYMET
|
$1.67 Billion |
|
China Tianying Inc
SHE:000035
|
$1.67 Billion |
|
China Aluminum International Engineering Corp Ltd
SHG:601068
|
$1.67 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in PHARVARIS N.V. EO -12's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 267,760,741 to 271,274,334, a change of 3,513,593 (1.3%).
- Net loss of 175,699,397 reduced equity.
- New share issuances of 171,737,647 increased equity.
- Other factors increased equity by 7,475,343.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-175.70 Million | -64.77% |
| Share Issuances | €171.74 Million | +63.31% |
| Other Changes | €7.48 Million | +2.76% |
| Total Change | €- | 1.31% |
Book Value vs Market Value Analysis
This analysis compares PHARVARIS N.V. EO -12's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 7.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.07x to 7.54x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €6.18 | €31.35 | x |
| 2022-12-31 | €4.41 | €31.35 | x |
| 2023-12-31 | €7.34 | €31.35 | x |
| 2024-12-31 | €4.92 | €31.35 | x |
| 2025-12-31 | €4.16 | €31.35 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently PHARVARIS N.V. EO -12 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -64.77%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.11x
- Recent ROE (-64.77%) is below the historical average (-42.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -20.85% | 0.00% | 0.00x | 1.03x | €-63.23 Million |
| 2022 | -51.14% | 0.00% | 0.00x | 1.12x | €-91.26 Million |
| 2023 | -26.27% | 0.00% | 0.00x | 1.04x | €-139.28 Million |
| 2024 | -50.13% | 0.00% | 0.00x | 1.09x | €-161.00 Million |
| 2025 | -64.77% | 0.00% | 0.00x | 1.11x | €-202.83 Million |
Industry Comparison
This section compares PHARVARIS N.V. EO -12's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $702,920,113
- Average return on equity (ROE) among peers: -93.80%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| PHARVARIS N.V. EO -12 (9EN) | €271.27 Million | -20.85% | 0.11x | $1.67 Billion |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $-294.00K | 0.00% | 0.00x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $41.39 Million | -67.94% | 2.33x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $3.94 Million | -301.40% | 1.87x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $175.54 Million | -32.14% | 1.02x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $230.94 Million | -20.03% | 0.13x | $189.29 Million |
| PreveCeutical Medical Inc (18H) | $-296.06K | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $5.50 Billion | 15.15% | 0.13x | $41.67 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $32.50 Million | -376.16% | 5.37x | $825.52 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.60 Million | -113.13% | 0.23x | $960.84K |
| ZAI LAB LTD0000006 (1ZLB) | $1.05 Billion | -42.40% | 0.17x | $1.82 Billion |
About PHARVARIS N.V. EO -12
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and a… Read more